Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 okt 2014 - 07:36
Statutaire naam
Galapagos NV
Titel
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
Bericht
Mechelen, Belgium; 20 October 2014 - Galapagos NV (Euronext: GLPG) discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October. Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84.
Datum laatste update: 09 augustus 2025